Cargando…
ABCC1 and glutathione metabolism limit the efficacy of BCL-2 inhibitors in acute myeloid leukemia
The BCL-2 inhibitor Venetoclax is a promising agent for the treatment of acute myeloid leukemia (AML). However, many patients are refractory to Venetoclax, and resistance develops quickly. ATP-binding cassette (ABC) transporters mediate chemotherapy resistance but their role in modulating the activi...
Autores principales: | Ebner, Jessica, Schmoellerl, Johannes, Piontek, Martin, Manhart, Gabriele, Troester, Selina, Carter, Bing Z., Neubauer, Heidi, Moriggl, Richard, Szakács, Gergely, Zuber, Johannes, Köcher, Thomas, Andreeff, Michael, Sperr, Wolfgang R., Valent, Peter, Grebien, Florian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10509209/ https://www.ncbi.nlm.nih.gov/pubmed/37726279 http://dx.doi.org/10.1038/s41467-023-41229-2 |
Ejemplares similares
-
SBNO2 is a critical mediator of STAT3-driven hematological malignancies
por: Brandstoetter, Tania, et al.
Publicado: (2023) -
BRD4: A BET(ter) target for the treatment of AML?
por: Valent, Peter, et al.
Publicado: (2014) -
A new fluorescent dye accumulation assay for parallel measurements of the ABCG2, ABCB1 and ABCC1 multidrug transporter functions
por: Szabó, Edit, et al.
Publicado: (2018) -
Three novel ABCC5 splice variants in human retina and their role as regulators of ABCC5 gene expression
por: Stojic, Jelena, et al.
Publicado: (2007) -
ABCG2 is not able to catalyze glutathione efflux and does not contribute to GSH-dependent collateral sensitivity
por: Gauthier, Charlotte, et al.
Publicado: (2013)